Literature DB >> 23438478

Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells.

Saritha Chakilam1, Muktheshwar Gandesiri, Tilman T Rau, Abbas Agaimy, Mahadevan Vijayalakshmi, Jelena Ivanovska, Ralph M Wirtz, Jan Schulze-Luehrmann, Natalya Benderska, Nadine Wittkopf, Ajithavalli Chellappan, Petra Ruemmele, Michael Vieth, Margret Rave-Fränk, Hans Christiansen, Arndt Hartmann, Clemens Neufert, Raja Atreya, Christoph Becker, Pablo Steinberg, Regine Schneider-Stock.   

Abstract

The TNF-IL-6-STAT3 pathway plays a crucial role in promoting ulcerative colitis-associated carcinoma (UCC). To date, the negative regulation of STAT3 is poorly understood. Interestingly, intestinal epithelial cells of UCC in comparison to ulcerative colitis show high expression levels of anti-inflammatory death-associated protein kinase (DAPK) and low levels of pSTAT3. Accordingly, epithelial DAPK expression was enhanced in STAT3(IEC-KO) mice. To unravel a possible regulatory mechanism, we used an in vitro TNF-treated intestinal epithelial cell model. We identified a new function of DAPK in suppressing TNF-induced STAT3 activation as DAPK siRNA knockdown and treatment with a DAPK inhibitor potentiated STAT3 activation, IL-6 mRNA expression, and secretion. DAPK attenuated STAT3 activity directly by physical interaction shown in three-dimensional structural modeling. This model suggests that DAPK-induced conformational changes in the STAT3 dimer masked its nuclear localization signal. Alternatively, pharmacological inactivation of STAT3 led to an increase in DAPK mRNA and protein levels. Chromatin immunoprecipitation showed that STAT3 restricted DAPK expression by promoter binding, thereby reinforcing its own activation by inducing IL-6. This novel negative regulation principle might balance TNF-induced inflammation and seems to play an important role in the inflammation-associated transformation process as confirmed in an AOM+DSS colon carcinogenesis mouse model. DAPK as a negative regulator of STAT3 emerges as therapeutic option in the treatment of ulcerative colitis and UCC.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438478      PMCID: PMC6719660          DOI: 10.1016/j.ajpath.2012.11.026

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  12 in total

1.  LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.

Authors:  Feng Yao; Weizheng Zhou; Chenxi Zhong; Wentao Fang
Journal:  Tumour Biol       Date:  2015-05-07

Review 2.  Insights into the functions of the death associated protein kinases from C. elegans and other invertebrates.

Authors:  Marian Chuang; Andrew D Chisholm
Journal:  Apoptosis       Date:  2014-02       Impact factor: 4.677

3.  IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis.

Authors:  Ying-Ying Chen; Zhi-Bin Ma; Hong-Yu Xu; Li-Jun Shi; Dong-Yue Li; Li-Ying Sun; Xun-Hai Yin; Guo-Yin Sang; Dan Xu; Yin-Hua Tang; Xi Wang; Peng Li; Feng Wu; Jin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 4.  Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review).

Authors:  Sara Steinmann; Kristina Scheibe; Katharina Erlenbach-Wuensch; Clemens Neufert; Regine Schneider-Stock
Journal:  Int J Oncol       Date:  2015-05-11       Impact factor: 5.650

5.  Repeated H2 O2 exposure drives cell cycle progression in an in vitro model of ulcerative colitis.

Authors:  Angela Poehlmann; Kathrin Reissig; Peter Schönfeld; Diana Walluscheck; Antje Schinlauer; Roland Hartig; Wiebke Lessel; Thomas Guenther; Andrew Silver; Albert Roessner
Journal:  J Cell Mol Med       Date:  2013-10-09       Impact factor: 5.310

6.  miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis.

Authors:  Natalya Benderska; Anna-Lena Dittrich; Sabine Knaup; Tilman T Rau; Clemens Neufert; Sven Wach; Fabian B Fahlbusch; Manfred Rauh; Ralph M Wirtz; Abbas Agaimy; Swetha Srinivasan; Vijayalakshmi Mahadevan; Petra Rümmele; Emmanouela Rapti; Maria Gazouli; Arndt Hartmann; Regine Schneider-Stock
Journal:  Inflamm Bowel Dis       Date:  2015-09       Impact factor: 5.325

7.  DAPK interacts with Patronin and the microtubule cytoskeleton in epidermal development and wound repair.

Authors:  Marian Chuang; Tiffany I Hsiao; Amy Tong; Suhong Xu; Andrew D Chisholm
Journal:  Elife       Date:  2016-09-23       Impact factor: 8.140

8.  Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: implication for tissue function and oncogenesis.

Authors:  John P Vanden Heuvel; Jerry T Thompson; Prajakta Albrecht; Donald Mandetta; Harry Kamerow; John P Ford
Journal:  Invest New Drugs       Date:  2015-07-01       Impact factor: 3.850

9.  DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer.

Authors:  TaeWoo Kwon; HyeSook Youn; Beomseok Son; Daehoon Kim; Ki Moon Seong; Sungkyun Park; Wanyeon Kim; BuHyun Youn
Journal:  Oncotarget       Date:  2016-02-09

10.  DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells.

Authors:  Jelena Ivanovska; Inti Zlobec; Stefan Forster; Eva Karamitopoulou; Heather Dawson; Viktor Hendrik Koelzer; Abbas Agaimy; Fabian Garreis; Stephan Söder; William Laqua; Alessandro Lugli; Arndt Hartmann; Tilman T Rau; Regine Schneider-Stock
Journal:  Oncotarget       Date:  2015-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.